A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent
or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the
dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD)
for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study
will also be determined.